Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Bone Mineral Density of Osteoporotic and Osteopenia Menopausal Women Treated With Oral Bisphosphonates Before Stopping the Treatment and 1 Year After Drug Holiday Period Publisher Pubmed



Rizi MM1 ; Salari A2 ; Salesi M1 ; Rasooli L1 ; Karimifar M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Rheumatology, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Clinical Rheumatology Published:2024


Abstract

Background: Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients’ BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH. Material and methods: A total of 202 patients were selected with osteopenia (n = 95) and osteoporosis (n = 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device. Result: The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (p = 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (p = 0.001). Conclusion: In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health. (Table presented.). © The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024.
Other Related Docs
16. Osteoporosis Screening Tools in Iranian Postmenopausal Women, Iranian Red Crescent Medical Journal (2010)
25. Air Pollution and Bone Mineral Density, Advances in Health and Disease (2021)
32. Report of Two Cases of Seronegative Rheumatoid Arthritis, Journal of Isfahan Medical School (2011)
36. Antioxidant and Bone; Protect Your Future: A Brief Review, Iranian Journal of Public Health (2021)
39. Intravenous Pamidronate for Refractory Rheumatoid Arthritis, Journal of Research in Medical Sciences (2012)
49. Evaluation of Bone Loss in Diabetic Postmenopausal Women, Journal of Research in Medical Sciences (2012)